Zobrazeno 1 - 10
of 35
pro vyhledávání: '"David F. Claxton"'
Autor:
Jeff Sivik, Chenchen Zhao, Natthapol Songdej, Todd D. Schell, Witold B. Rybka, David F. Claxton, Seema Naik, Hong Zheng, Ming Wang, W. Christopher Ehmann, Bei Jia, Raymond J. Hohl, Hui Zeng, Shin Mineishi
Publikováno v:
British Journal of Haematology
Summary Decitabine is a DNA‐hypomethylating agent that has been widely applied for the treatment of acute myeloid leukaemia (AML) patients who are elderly or unfit for intensive therapy. Although effective, the complete response rate to decitabine
Autor:
Charyguly Annageldiyev, Nicole R. Keasey, Emily Sullivan, Paul T. Toran, Hong Gang Wang, Regina M. Ondrasik, Su Fern Tan, Andrea L. Cote, Tye G. Deering, Todd E. Fox, David J. Feith, Brian M. Barth, Timothy J Brown, Stephan T. Stern, Mark Kester, David F. Claxton, Thomas P. Loughran, Vasiliki Papakotsi, Arati Sharma, Ross L. Levine, David B. Needle, Junjia Zhu, Sriram S. Shanmugavelandy, Aaron D. Viny, Viola Devine, Weiyuan Wang, Jason Liao
Publikováno v:
Blood Advances. 3:2598-2603
Key Points Distinct sphingolipid metabolism of AML with MDS-related changes defines unique sensitivity to nanoliposomal C6-ceramide. Vinblastine alters sphingolipid metabolism to enhance the sensitivity of AML to nanoliposomal C6-ceramide.
Autor:
Pau Montesinos, Farhad Ravandi, Martha Arellano, Karen Seiter, Ellin Berman, Jessica K. Altman, Lori J. Maness, Donald P. Quick, Parameswaran Venugopal, Judy H. Chiao, Scott R. Solomon, Rakesh Gaur, Mikkael A. Sekeres, Maria R. Baer, Marc Buyse, Aleksandra Butrym, David A. Rizzieri, Stephen A. Strickland, Stuart L. Goldberg, Tapan M. Kadia, Marc Gautier, David F. Claxton, Gary J. Schiller, Gianluca Gaidano, Kebede H. Begna, Selina M. Luger, Hagop M. Kantarjian, Xavier Thomas
Publikováno v:
Cancer
CANCER
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Cancer, vol 127, iss 23
CANCER
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Cancer, vol 127, iss 23
BackgroundAcute myeloid leukemia (AML) is fatal in elderly patients who are unfit for standard induction chemotherapy. The objective of this study was to evaluate the survival benefit of administering sapacitabine, an oral nucleoside analogue, in alt
Autor:
Dhimant Desai, Mark R. Conaway, Thomas P. Loughran, Hong Gang Wang, Samy A.F. Morad, Kenichiro Doi, Xin Liu, David J. Feith, Todd E. Fox, Su Fern Tan, Mark Kester, Myles C. Cabot, David F. Claxton, Wendy Dunton, Shantu Amin
Publikováno v:
Journal of Lipid Research, Vol 60, Iss 6, Pp 1078-1086 (2019)
J Lipid Res
J Lipid Res
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. More than half of older AML patients fail to respond to cytotoxic chemotherapy, and most responders relapse with drug-resistant disease. Failure to achieve complete remission c
Autor:
Elisabeth Paietta, Zhuoxin Sun, Martin S. Tallman, Neil E. Kay, Natalie S. Callander, Sanford Kempin, Rhett P. Ketterling, Gordan Srkalovic, David F. Claxton, Gerald Gross, Joseph J. Mazza, Olga Frankfurt, Joel N. Saltzman
Publikováno v:
Acta Haematol
Patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) may benefit from salvage chemoimmunotherapy (CIT). To explore further the use of CIT in the pre-novel agent era, ECOG-ACRIN undertook a phase 2 trial (E2903) for R/R CLL utili
Autor:
Amit Verma, Selina M. Luger, Zhuoxin Sun, Puneet S. Cheema, Jaroslaw P. Maciejewski, Martin S. Tallman, Mark R. Litzow, David F. Claxton, Jessica K. Altman, Rami S. Komrokji, John M. Bennett, Alan F. List, Kathy L. McGraw, Ryan J. Mattison, Charles A. Schiffer, Andrew S. Artz, Timothy R. Wassenaar
Publikováno v:
J Clin Oncol
PURPOSE Impaired response to erythropoietin underlies ineffective erythropoiesis and anemia in myelodysplastic syndromes (MDS). We investigated whether treatment with lenalidomide (LEN), which augments erythropoietin receptor signaling in vitro, can
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b527e937e93c76976bde4e0ca2a12342
https://europepmc.org/articles/PMC8274743/
https://europepmc.org/articles/PMC8274743/
Autor:
Pinyi Lu, Longgui Chen, Barbara A. Miller, Zhongming Zhao, Charyguly Annageldiyev, Melat T. Gebru, Christopher M. Dower, Jennifer M. Atkinson, Arati Sharma, Megan M. Young, Zhenyuan Tang, Hong Gang Wang, Lijun Zhang, David F. Claxton, Yuka Imamura Kawasawa, Zhenqiu Liu
Publikováno v:
Blood
FLT3 is a frequently mutated gene that is highly associated with a poor prognosis in acute myeloid leukemia (AML). Despite initially responding to FLT3 inhibitors, most patients eventually relapse with drug resistance. The mechanism by which resistan
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c7a15350f4c228b28961190773dd4afe
https://europepmc.org/articles/PMC7453151/
https://europepmc.org/articles/PMC7453151/
Autor:
Amriti R. Lulla, Jeffrey J. Pu, Jawad Babar, Nadia Khan, Cyril H. Benes, Lanlan Zhou, Joshua E. Allen, A. Pieter J. van den Heuvel, Ultan McDermott, Mala K. Talekar, Mathew J. Garnett, C. Leah B. Kline, Junior Hall, Wolfgang Oster, David F. Claxton, Varun V. Prabhu, David T. Dicker, Wafik S. El-Deiry, Stephan A. Grupp
Publikováno v:
Cell Cycle. 17:468-478
ONC201, founding member of the imipridone class of small molecules, is currently being evaluated in advancer cancer clinical trials. We explored single agent and combinatorial efficacy of ONC201 in preclinical models of hematological malignancies. ON
Autor:
Kosuke Miki, Kevin Rakszawski, Shin Mineishi, Seema Naik, Henry N. Wagner, David F. Claxton, Hiroko Shike
Publikováno v:
International Journal of Hematology. 108:348-350
Approximately 30-40% of patients with acute myeloid leukemia (AML) experience induction failures. In these patients who do not achieve remission with two cycles of standard induction therapies, the probability of achieving remission with subsequent i
Autor:
Miki Kassai, Samy A.F. Morad, Li-Pin Kao, Traci S. Davis, Noha Abdelmageed, Gemma Fabriàs, Thomas P. Loughran, José L. Abad, Sarah Spiegel, Su Fern Tan, David J. Feith, Todd E. Fox, Mark Kester, Kelsey H. Fisher-Wellman, Matthew R. MacDougall, Myles C. Cabot, David F. Claxton
Publikováno v:
J Lipid Res
Journal of Lipid Research, Vol 60, Iss 9, Pp 1590-1602 (2019)
Digital.CSIC. Repositorio Institucional del CSIC
instname
Journal of Lipid Research, Vol 60, Iss 9, Pp 1590-1602 (2019)
Digital.CSIC. Repositorio Institucional del CSIC
instname
The combination of daunorubicin (dnr) and cytarabine (Ara-C) is a cornerstone of treatment for acute myelogenous leukemia (AML); resistance to these drugs is a major cause of treatment failure. Ceramide, a sphingolipid (SL), plays a critical role in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4532efe4cdccaac86289135ec63a5056
http://hdl.handle.net/10261/189423
http://hdl.handle.net/10261/189423